Cardiff Oncology, Inc. SEC filings CRDF
Cardiff Oncology, Inc. has 1,001 filings in SEC EDGAR's recent list, going back to May 23, 2012. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 27, 2026 (officer or director change, bylaw or fiscal year change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Aug 26, 2026 | — |
| DEF 14A | Proxy statement | Aug 26, 2026 | Aug 26, 2026 |
| PRE 14A | Preliminary proxy statement | Aug 14, 2026 | Aug 14, 2026 |
| DEFA14A | Additional proxy material | Apr 23, 2026 | — |
| DEF 14A | Proxy statement | Apr 23, 2026 | Jun 11, 2026 |
| DEFA14A | Additional proxy material | Apr 30, 2025 | — |
| DEF 14A | Proxy statement | Apr 29, 2025 | Apr 29, 2025 |
| DEFA14A | Additional proxy material | Jun 17, 2024 | — |
| DEFA14A | Additional proxy material | Jun 3, 2024 | — |
| DEFA14A | Additional proxy material | Apr 25, 2024 | — |
| DEF 14A | Proxy statement | Apr 25, 2024 | Jun 20, 2024 |
| DEFA14A | Additional proxy material | Apr 27, 2023 | — |
| DEF 14A | Proxy statement | Apr 27, 2023 | — |
| DEFA14A | Additional proxy material | Apr 15, 2022 | — |
| DEF 14A | Proxy statement | Apr 14, 2022 | Jun 9, 2022 |
| DEFA14A | Additional proxy material | Apr 28, 2021 | — |
| DEF 14A | Proxy statement | Apr 28, 2021 | Jun 10, 2021 |
| DEF 14A | Proxy statement | Mar 4, 2020 | Apr 16, 2020 |
| DEFA14A | Additional proxy material | Apr 23, 2019 | — |
| DEF 14A | Proxy statement | Apr 19, 2019 | Jun 6, 2019 |
| DEFA14A | Additional proxy material | Jan 31, 2019 | — |
| DEFA14A | Additional proxy material | Jan 15, 2019 | — |
| DEF 14A | Proxy statement | Dec 18, 2018 | Jan 15, 2019 |
| PRE 14A | Preliminary proxy statement | Dec 10, 2018 | Dec 7, 2018 |
| DEF 14A | Proxy statement | Apr 27, 2018 | May 30, 2018 |
| PRE 14A | Preliminary proxy statement | Apr 16, 2018 | May 30, 2018 |
| DEFA14A | Additional proxy material | Apr 28, 2017 | — |
| DEF 14A | Proxy statement | Apr 28, 2017 | Jun 13, 2017 |
| DEFA14A | Additional proxy material | Mar 31, 2016 | — |
| DEF 14A | Proxy statement | Mar 31, 2016 | May 17, 2016 |
| DEFA14A | Additional proxy material | Dec 9, 2015 | — |
| DEFA14A | Additional proxy material | Oct 16, 2015 | — |
| DEF 14A | Proxy statement | Oct 16, 2015 | Dec 9, 2015 |
| PRE 14A | Preliminary proxy statement | Oct 5, 2015 | Dec 9, 2015 |
| DEFA14A | Additional proxy material | Apr 20, 2015 | — |
| DEF 14A | Proxy statement | Apr 20, 2015 | Jun 10, 2015 |
| PRE 14A | Preliminary proxy statement | Apr 10, 2015 | Jun 10, 2015 |
| DEFA14A | Additional proxy material | Jul 24, 2014 | — |
| DEF 14A | Proxy statement | Jul 23, 2014 | Sep 17, 2014 |
| DEFA14A | Additional proxy material | Jul 2, 2013 | — |
| DEFA14A | Additional proxy material | Jun 14, 2013 | — |
| DEF 14A | Proxy statement | May 29, 2013 | Jul 18, 2013 |
| PRE 14A | Preliminary proxy statement | May 16, 2013 | Jul 18, 2013 |
| DEFA14A | Additional proxy material | Oct 19, 2012 | — |
| DEF 14A | Proxy statement | Oct 18, 2012 | Dec 10, 2012 |
Showing 45 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CRDF (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1213037
- Former names
- Trovagene, Inc. (until May 7, 2020); TrovaGene Inc. (until Mar 4, 2013); XENOMICS INC (until Jun 3, 2009); USED KAR PARTS INC (until Jun 30, 2004)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.